Stereotactic Body Proton Therapy for Liver Tumors: Dosimetric Advantages and Their Radiobiological and Clinical Implications

Overview

Journal Phys Imaging Radiat Oncol

Specialty Oncology

Date 2021 Jan 18

PMID 33458411

Citations 9

Authors

W Tristram Arscott

Reid F Thompson

Lingshu Yin

Brendan Burgdorf

Maura Kirk

Edgar Ben-Josef

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Photon Stereotactic Body Radiotherapy (SBRT) for primary and metastatic tumors of the liver is challenging for larger lesions. An comparison of paired SBRT and Stereotactic Body Proton Therapy (SBPT) plans was performed to understand the potential advantages of SBPT as a function of tumor size and location.

Methods And Materials: Theoretical tumor volumes with maximum diameter of 1-10 cm were contoured in the dome, right inferior, left medial, and central locations. SBRT and SBPT plans were generated to deliver 50 Gy in 5 fractions, max dose <135%. When organs-at-risk (OAR) constraints were exceeded, hypothetical plans (not clinically acceptable) were generated for comparison. Liver normal tissue complication probability (NTCP) models were applied to evaluate differences between treatment modalities.

Results: SBRT and SBPT were able to meet target goals and OAR constraints for lesions up to 7 cm and 9 cm diameter, respectively. SBPT plans resulted in a higher integral gross target dose for all lesions up to 7 cm (mean dose 57.8 ± 2.3 Gy to 64.1 ± 2.2 Gy,  < 0.01). Simultaneously, SBPT spared dose to the uninvolved liver in all locations (from 11.5 ± 5.3 Gy to 8.6 ± 4.4 Gy,  < 0.01), resulting in lower NTCP particularly for larger targets in the dome and central locations. SBPT also spared duodenal dose across all sizes and positions (from 7.3 ± 1.1 Gy to 1.1 ± 0.3 Gy,  < 0.05).

Conclusion: The main advantages of SBPT over SBRT is meeting plan goals and constrains for larger targets, particularly dome and central locations, and sparing dose to uninvolved liver. For such patients, SBPT may allow improvements in tumor control and treatment safety.

Citing Articles

New guidelines and recommendations to advance treatment planning in proton therapy.

Knausl B, Vestergaard A, Schwarz M, Muren L Phys Imaging Radiat Oncol. 2025; 33:100695.

PMID: 39866245 PMC: 11764265. DOI: 10.1016/j.phro.2024.100695.

Dosimetric comparison of proton therapy and CyberKnife in stereotactic body radiation therapy for liver cancers.

Shyllon S, Penfold S, Dalfsen R, Kirkness E, Hug B, Rowshanfarzad P Phys Eng Sci Med. 2024; 47(3):1203-1212.

PMID: 38809365 PMC: 11408538. DOI: 10.1007/s13246-024-01440-x.

High dose proton and photon-based radiation therapy for 213 liver lesions: a multi-institutional dosimetric comparison with a clinical perspective.

Bonu M, Nicosia L, Turkaj A, Pastorello E, Vitali P, Frassine F Radiol Med. 2024; 129(3):497-506.

PMID: 38345714 PMC: 10942931. DOI: 10.1007/s11547-024-01788-w.

Challenges and opportunities in stereotactic body proton radiotherapy of liver malignancies.

Li H, Ger R, Narang A, Chen H, Meyer J J Radiosurg SBRT. 2023; 9(1):83-90.

PMID: 38029013 PMC: 10681149.

Proton liver stereotactic body radiation therapy: Treatment techniques and dosimetry feasibility from a single institution.

Zhou J, Kang M, Wang Y, Higgins K, Simone C, Patel P J Radiosurg SBRT. 2023; 9(1):33-42.

PMID: 38029011 PMC: 10681147.

References

Petersen J, Lassen Y, Hansen A, Muren L, Grau C, Hoyer M . Normal liver tissue sparing by intensity-modulated proton stereotactic body radiotherapy for solitary liver tumours. Acta Oncol. 2011; 50(6):823-8. DOI: 10.3109/0284186X.2011.590526. View

Barry A, McPartlin A, Lindsay P, Wang L, Brierley J, Kim J . Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy. Pract Radiat Oncol. 2017; 7(5):e331-e337. DOI: 10.1016/j.prro.2017.03.004. View

Toramatsu C, Katoh N, Shimizu S, Nihongi H, Matsuura T, Takao S . What is the appropriate size criterion for proton radiotherapy for hepatocellular carcinoma? A dosimetric comparison of spot-scanning proton therapy versus intensity-modulated radiation therapy. Radiat Oncol. 2013; 8:48. PMC: 3606425. DOI: 10.1186/1748-717X-8-48. View

Ben-Josef E, Normolle D, Ensminger W, Walker S, Tatro D, Ten Haken R . Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005; 23(34):8739-47. DOI: 10.1200/JCO.2005.01.5354. View

Goodman K, Wiegner E, Maturen K, Zhang Z, Mo Q, Yang G . Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010; 78(2):486-93. DOI: 10.1016/j.ijrobp.2009.08.020. View

Hong T, Wo J, Yeap B, Ben-Josef E, McDonnell E, Blaszkowsky L . Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2015; 34(5):460-8. PMC: 4872014. DOI: 10.1200/JCO.2015.64.2710. View

Su T, Lu H, Cheng T, Zhou Y, Huang Y, Gao Y . Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm. BMC Cancer. 2016; 16(1):834. PMC: 5093984. DOI: 10.1186/s12885-016-2894-9. View

Gandhi S, Liang X, Ding X, Zhu T, Ben-Josef E, Plastaras J . Clinical decision tool for optimal delivery of liver stereotactic body radiation therapy: Photons versus protons. Pract Radiat Oncol. 2015; 5(4):209-18. DOI: 10.1016/j.prro.2015.01.004. View

Velec M, Haddad C, Craig T, Wang L, Lindsay P, Brierley J . Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2017; 97(5):939-946. DOI: 10.1016/j.ijrobp.2017.01.221. View

10.

Cardenes H, Price T, Perkins S, Maluccio M, Kwo P, Breen T . Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010; 12(3):218-25. DOI: 10.1007/s12094-010-0492-x. View

11.

Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C . The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol. 2015; 141(7):1301-9. DOI: 10.1007/s00432-015-1929-y. View

12.

Weiner A, Olsen J, Ma D, Dyk P, DeWees T, Myerson R . Stereotactic body radiotherapy for primary hepatic malignancies - Report of a phase I/II institutional study. Radiother Oncol. 2016; 121(1):79-85. PMC: 5543719. DOI: 10.1016/j.radonc.2016.07.020. View

13.

Swaminath A, Massey C, Brierley J, Dinniwell R, Wong R, Kim J . Accumulated Delivered Dose Response of Stereotactic Body Radiation Therapy for Liver Metastases. Int J Radiat Oncol Biol Phys. 2015; 93(3):639-48. DOI: 10.1016/j.ijrobp.2015.07.2273. View

14.

Culleton S, Jiang H, Haddad C, Kim J, Brierley J, Brade A . Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol. 2014; 111(3):412-7. DOI: 10.1016/j.radonc.2014.05.002. View

15.

Tsai Y, Tsai C, Hsu F, Jian-Kuen W, Chien-Jang W, Cheng J . Superior liver sparing by combined coplanar/noncoplanar volumetric-modulated arc therapy for hepatocellular carcinoma: a planning and feasibility study. Med Dosim. 2013; 38(4):366-71. DOI: 10.1016/j.meddos.2013.04.003. View

16.

Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, Clerici E . Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2014; 141(3):543-53. DOI: 10.1007/s00432-014-1833-x. View

17.

Eccles C, Bissonnette J, Craig T, Taremi M, Wu X, Dawson L . Treatment planning study to determine potential benefit of intensity-modulated radiotherapy versus conformal radiotherapy for unresectable hepatic malignancies. Int J Radiat Oncol Biol Phys. 2008; 72(2):582-8. DOI: 10.1016/j.ijrobp.2008.06.1496. View

18.

Thomas E, Chapet O, Kessler M, Lawrence T, Ten Haken R . Benefit of using biologic parameters (EUD and NTCP) in IMRT optimization for treatment of intrahepatic tumors. Int J Radiat Oncol Biol Phys. 2005; 62(2):571-8. DOI: 10.1016/j.ijrobp.2005.02.033. View

19.

Jung J, Yoon S, Kim S, Cho B, Park J, Kim S . Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. Radiat Oncol. 2013; 8:249. PMC: 3816573. DOI: 10.1186/1748-717X-8-249. View

20.

Spalding A, Jee K, Vineberg K, Jablonowski M, Fraass B, Pan C . Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med Phys. 2007; 34(2):521-9. DOI: 10.1118/1.2426403. View